Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47%TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) ...
September 30, 2026, 10:01 to October 7, 2026, 10:01 (JST)This week, progress was made in preparing for U.S. regulatory ...
PACE is the first phase 3 randomized trial directly comparing radical prostatectomy with SBRT in men with low- to intermediate-risk prostate cancer.
August–September 2026 / bladder cancer, cancer, cancer care, Cancer research, cancer treatment, chemotherapy, clinical trials ...
Medicana Health Group is highlighting the role of robot-assisted surgery in prostate cancer treatment as a 2026 research ...
Roughly 1 in 8 men receive a prostate cancer diagnosis at some stage in their lives, but only about 1 in 44 men will die of ...
Five-treatment stereotactic body radiation therapy (SBRT) provided excellent long-term cancer control with fewer urinary ...
Five-treatment stereotactic body radiation therapy (SBRT) provided excellent long-term cancer control with fewer urinary and ...
Stereotactic body radiation therapy significantly improved quality of life outcomes, including urinary incontinence and ...
Five-treatment stereotactic body radiation therapy (SBRT) provided excellent long-term cancer control with fewer urinary and ...
Thousands of men with prostate cancer could avoid the debilitating urinary and sexual side effects of surgery, thanks to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results